ATE297553T1 - Verfahren zum screening der apoptosis und necrose - Google Patents

Verfahren zum screening der apoptosis und necrose

Info

Publication number
ATE297553T1
ATE297553T1 AT99900070T AT99900070T ATE297553T1 AT E297553 T1 ATE297553 T1 AT E297553T1 AT 99900070 T AT99900070 T AT 99900070T AT 99900070 T AT99900070 T AT 99900070T AT E297553 T1 ATE297553 T1 AT E297553T1
Authority
AT
Austria
Prior art keywords
necrosis
apoptotic
pro
necrotic
screening apoptosis
Prior art date
Application number
AT99900070T
Other languages
English (en)
Inventor
Thomas Harr
Alessandro Strebel
Peter Erb
Sinuhe Hahn
Original Assignee
Hemolytics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemolytics Ag filed Critical Hemolytics Ag
Application granted granted Critical
Publication of ATE297553T1 publication Critical patent/ATE297553T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99900070T 1998-01-12 1999-01-12 Verfahren zum screening der apoptosis und necrose ATE297553T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98100369A EP0928968A1 (de) 1998-01-12 1998-01-12 Verfahren zum Screening der Apoptosis und Necrose
PCT/IB1999/000030 WO1999035493A1 (en) 1998-01-12 1999-01-12 Screening method for apoptosis and necrosis

Publications (1)

Publication Number Publication Date
ATE297553T1 true ATE297553T1 (de) 2005-06-15

Family

ID=8231252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99900070T ATE297553T1 (de) 1998-01-12 1999-01-12 Verfahren zum screening der apoptosis und necrose

Country Status (7)

Country Link
US (2) US6723567B1 (de)
EP (2) EP0928968A1 (de)
JP (1) JP2002500863A (de)
AT (1) ATE297553T1 (de)
CA (1) CA2317463A1 (de)
DE (1) DE69925710D1 (de)
WO (1) WO1999035493A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202098A1 (en) 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
AU2002226244A1 (en) * 2002-02-04 2003-09-02 Hemolytics Ag High throughput screening method for compounds with non-, pro-, or anti-apoptotic or proliferative or necrotic activity
DE10318048A1 (de) * 2003-04-17 2004-11-04 Axaron Bioscience Ag Nicht fluoreszierende, durch Proteolyse zur Fluoreszenz aktivierbare Reporterproteine und ihre Verwendung zur Detektion Protease-abhängiger Ereignisse
JP4991544B2 (ja) 2004-08-23 2012-08-01 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
WO2007065080A2 (en) * 2005-11-29 2007-06-07 University Of Maryland, College Park Control of apoptosis by controlling the propensity of ceramide channel formation
CN102719465B (zh) * 2011-03-29 2014-01-08 复旦大学 可诱导性组织特异性表达载体及其用途
EP2715350B1 (de) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Verwendung einer akt-phosphorylierung als biomarker zur prognose neurodegenerativer erkrankungen und zu ihrer behandlung
WO2020012478A2 (en) 2018-07-11 2020-01-16 Immunity Pharma Ltd. Peptide compounds and therapeutic uses of same
IL272074A (en) 2020-01-15 2021-07-29 Immunity Pharma Ltd Peptide compounds and their use in methods of treating diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2824155B2 (ja) * 1994-04-11 1998-11-11 ネクシンズ・リサーチ・ベー・ブイ 試料中の又は試料からアポトーシス細胞を検出し及び／又は場合により定量し及び／又は分離するための方法
US5958713A (en) * 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
DK0851874T3 (da) * 1995-09-22 2000-03-06 Bioimage A S Hidtil ukendte varianter af grønt fluorescerende protein, GFP
WO1997014812A2 (en) * 1995-10-16 1997-04-24 Chiron Corporation Method of screening for factors that modulate gene expression
DE69714338T2 (de) * 1996-05-10 2003-02-13 Becton Dickinson Co Verfahren und Vorrichtung zum Nachweis eines malignen Potentials in Gewebezellen
US6037461A (en) * 1997-05-20 2000-03-14 Thomas Jefferson University FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
US5945291A (en) * 1997-11-10 1999-08-31 Coulter International Corp. Method for distinguishing viable, early apoptotic, late apoptotic, and necrotic cells

Also Published As

Publication number Publication date
DE69925710D1 (de) 2005-07-14
EP1047937A1 (de) 2000-11-02
JP2002500863A (ja) 2002-01-15
CA2317463A1 (en) 1999-07-15
WO1999035493A1 (en) 1999-07-15
EP0928968A1 (de) 1999-07-14
EP1047937B1 (de) 2005-06-08
US6723567B1 (en) 2004-04-20
US20040166545A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
IT8421007A0 (it) Procedimento e composizione per il mantenimento e la riparazione disuperfici contenenti asfalto e gomma.
DK1012274T4 (da) Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
ATE297553T1 (de) Verfahren zum screening der apoptosis und necrose
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
DK1051500T3 (da) Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme
DE3785788T2 (de) Vorrichtung zur Bewertung der Güte von Reiskörnern.
ATE294164T1 (de) Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening
DK0529065T3 (da) Receptorbaserede fremgangsmåder til screening for amylinagonister og -antagonister
BR9912545A (pt) ácidos nucleicos codificando um receptorcopulado a proteìna g envolvido em transduçãosensorial
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
EP1141237A4 (de) Pth rezeptor und testverfahren unter verwendung desselben
DE69819255D1 (de) Flüssige Amine enthaltende Zusammensetzung als Emulgiermittel für Bitume
DE3587488T2 (de) Gerät zur Bewertung der Dichte und Ebenheit von gedruckten Mustern.
ATE419356T1 (de) Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendung
DE69429085T2 (de) Verfahren zur Differenzierung der Quelle okkulter gastrointestinaler Blutungen
ATE488589T1 (de) Transkriptionaler intermediärfaktor 2
ATE469238T1 (de) Verwendung von fluor-nmr zum screening mit hohem durchsatz
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
ATE284955T1 (de) Map-kinase: polypeptide, polynukleotide und ihre verwendung
DK0923644T3 (da) G-koblet receptor, der udviser selektiv selektivitet for ATP
ATE256101T1 (de) Gelbe polymorphe form von 5-amino-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypro yl)-isophthalamid
NO892189L (no) Trijodbenzenforbindelser og kontrastmidler for radiografiinneholdende disse.
DE50015432D1 (de) Prüfeinrichtung zum prüfen von langgestreckten gegenständen
ATE286968T1 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren
DE58906749D1 (de) Verwendung von feststoffen als antiblockadditive für markierflüssigkeiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties